clinical trial · NCT06797999
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
Metastatic Soft Tissue SarcomaUnresectable Soft Tissue SarcomaAntibody-drug conjugate (ADC)
brief summary
The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
started
Jun 5, 2025
primary completion
Feb 27, 2029
completion
Feb 27, 2029
last updated
Jan 28, 2026
detailed description
Safety and Tolerability evaluated by incidence of DLTs. Efficacy evaluated by antitumor activity; ORR, DOR, PFS, CBR and TTR per RECIST v i.1.
official title
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol